Lenvatinib versus bevacizumab when combined with PD-1/L1 inhibitor and hepatic arterial infusion chemotherapy in unresectable hepatocellular carcinoma

Lenvatinib versus bevacizumab when combined with PD-1/L1 inhibitor and hepatic arterial infusion chemotherapy in unresectable hepatocellular carcinoma

IntroductionThe combination of anti-angiogenic agents, PD-1/L1 inhibitors, and hepatic arterial infusion chemotherapy (HAIC) has emerged as an important strategy for unresectable hepatocellular carcinoma (uHCC), yet comparative data on efficacy and safety between different anti-angiogenic agents (le...

Full description

Saved in:
Bibliographic Details
Main Authors: Lichang Huang, Yujie Xu, Na Liu, Hailong Chen, Zichao Wu, Qijiong Li, Minqiang Lu, Wei Wei, Yaojun Zhang, Minshan Chen, Li Xu, Ming Shi, Zhicheng Lai
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-05-01
Series:Frontiers in Immunology
Subjects:
hepatocellular carcinoma
lenvatinib
bevacizumab
combination therapy
potential resectable
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2025.1573098/full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2025.1573098/full

Similar Items